Top Ten most popular articles on Pharmafile.com this week

Summer seems to be in full swing as we reach the end of June, so it's time to look back on the most popular articles over the past week.

It was a week dominated with new drug approvals, particularly in the UK and Europe, in a range of indications including HIV, multiple sclerosis and lung cancer, while J&J's second most senior executive announces she is to leave the firm.

The most popular story this week, however, was the exciting news that Amgen's biosimilar version of J&J's Remicade proved itself to be no less effective than iits reference product in the treatment of moderate-to-severe rheumatoid arthritis,

Check out the week's ten most popular articles on Pharmafile.com now!

10. US hospital's ketamine study forced to a halt over consent concerns

Minneapolis-based hospital Hennepin County Medical Center has put the brakes on a clinical trial investigating the efficacy of ketamine in emergency situations after pressure from state officials.

9. AstraZeneca's Lynparza proves efficacy in first-line BRCA-mutated advanced ovarian cancer

AstraZeneca is celebrating alongside partner MSD with the reveal of new data on the use of Lynparza in the first-line treatment of BRCA-mutated advanced ovarian cancer.

8. NICE backs Sanofi’s new treatment for atopic dermatitis

NICE has recommended dupilumab, in combination with topical corticosteroids, for use on the NHS in England for the treatment of moderate to severe atopic dermatitis in adults when they have not responded to at least one other systemic therapy, such as immunosuppressants.

7. Roivant launches two new companies amid major restructure and staff layoffs

Roivant has announced it is to undergo a major restructure and launch two new business units alongside a new startup – a move which will also see the company shed a considerable number of staff.

6. AstraZeneca's Imfinzi becomes India's first available immunotherapy for lung cancer

In a big step forward for India as AstraZeneca announces that its checkpoint inhibitor Imfinzi has secured approval in the country from the DCGI to become the first available immunotherapy for the treatment of unresectable non-small cell lung cancer (NSCLC).

5. J&J's second-in-command to retire, alongside executive restructure

Johnson & Johnson’s Group Worldwide Chairman Sandra Peterson has announced she is to retire from her role and the company effective 1 October this year, triggering and executive-level shift at the firm.

4. Roche's Ocrevus cleared for NHS use in relapsing-remitting MS

Roche and multiple sclerosis (MS) patients across England and Wales are celebrating the news that healthcare watchdog NICE has recommended the use of Ocrevus (ocrelizumab) on the NHS in relapsing-remitting forms of the condition.

3. Working Life: Vertex Pharma's Simon Lem, VP, Regional General Manager of North Europe

Pharmafocus caught up with Vertex Pharma's Simon Lem to discuss his journey throughout the industry and the importance of the steps he's taken along the way in his personal and professional successes.

2. European Commission greenlights Gilead's Biktarvy for HIV-1

Gilead's Biktarvy has been awarded marketing authorisation in the European Union from the European Commission for the treatment of HIV-1 infection.

1. Amgen biosimilar proves non-inferior to J&J's Remicade in rheumatoid arthritis

Amgen has unveiled new Phase 3 data for its biosimilar version of Johnson & Johnson’s Remicade, confirming that it demonstrated non-inferiority compared to its reference product in the treatment of moderate-to-severe rheumatoid arthritis.